Clearmind Medicineの空売り状況は、投資家がClearmind Medicineの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Clearmind Medicine (NASDAQ:CMND) 株価情報, 空売り情報

Clearmind Medicine

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Clearmind Medicine Inc

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth initiates coverage on Actuate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) with a Buy rating and announces Price Target of $20.

News

Price Target

Initiation

Analyst Ratings

ACTU

HC Wainwright & Co. Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $20

HC Wainwright &amp; Co. analyst Oren Livnat reiterates ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Buy and maintains $94 price target.

Reiteration

ANIP

HC Wainwright & Co. Reiterates Buy on ANI Pharmaceuticals, Maintains $94 Price Target

B of A Securities analyst Ebrahim Poonawala maintains U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) with a Buy and lowers the price target from $50 to $49.

B of A Securities Maintains Buy on U.S. Bancorp, Lowers Price Target to $49

FLAMINGO-01 Data Safety Monitoring Board (DSMB)
The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been reported to date in FLAMINGO-01. Additional safety updates and comparison to the Phase IIb safety data are provided below.
Phase IIb Safety Data
In the prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites led by&nbsp;MD Anderson Cancer Center) Phase IIb clinical trial of HLA-A&#x2A;02 breast cancer patients, 46&nbsp;HER2/neu&nbsp;3+ over-expressor patients were treated with GLSI-100, and 50 placebo patients were&nbsp;treated with GM-CSF alone. After 5 years of follow-up, there was an 80% or greater reduction in&nbsp;cancer recurrences in the HER2/neu&nbsp;3+ patients who were treated with GLSI-100, followed, and&nbsp;remained disease free over the first 6 months, which we believe is the time required to reach peak immunity and thus maximum efficacy and protection. The Phase IIb results can be summarized as follows:
<ul>
<li>80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up compared to 20-50% reduction in recurrence rate by other approved products</li>
<li>Peak immune response at 6 months</li>
<li>No reported serious adverse events attributable to treatment</li>
<li>Well-tolerated safety profile</li>
</ul>
Full immunization was received in the Primary Immunization Series (PIS), which included the first 6 GLSI-100 injections over the first 6 months.&nbsp;The PIS elicited a potent immune response as measured by local skin tests and immunological assays. Further, booster injections given every 6 months prolonged the immune response, thereby providing longer-term protection. In the Phase IIb and three Phase I clinical trials,&nbsp;where 146 patients were treated,&nbsp;the GP2 immunotherapy was well tolerated, and there were no reported serious adverse events related to GLSI-100.
The Phase IIb safety data was published at ASCO in 2021 with the following findings:
<ul>
<li>GP2 immunotherapy is well-tolerated and no safety signal for GP2 was identified. Additionally, no serious adverse events related to GP2 immunotherapy were reported over the full 5 year treatment and follow-up periods. &nbsp;</li>
<li>The majority of patients experienced mild or moderate injection site reactions, which accounted for approximately 70% of reported adverse events. &nbsp;</li>
<li>The incidence of adverse events was similar across HER2 3+ and HER2 1-2+ breast cancer patients, consistent with the previously reported findings that the immune response was similar across both patient populations. This suggests that GP2 immunotherapy could be a potential treatment in HER2 1-2+ patients or in other HER2 expressing cancers. &nbsp;</li>
</ul>
FLAMINGO-01 Safety Data
Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. The open label safety data is based on the patients enrolled to date in FLAMINGO-01 and is thus preliminary. While comparing this preliminary FLAMINGO-01 data to the Phase IIb clinical trial data is possible, these preliminary results from FLAMINGO-01 are not a prediction of future results. It is important to note that this preliminary summary may not reflect results at the end of the study.
A preliminary review of FLAMINGO-01 safety data in both the HLA-A&#x2A;02 treated and placebo arms and the third open label arm with all other HLA types, shows that GP2 immunotherapy continues to be well-tolerated and that no safety signal for GP2 has yet to be identified across all arms of the study. Like the Phase IIb clinical trial, the most frequent adverse event is injection site reaction, which is also a sign of an immune response. As the study matures, the frequency of events related to GLSI-100 will increase, which based on the current data, suggests that the FLAMINGO-01 safety data is trending towards a similar safety profile to that of the Phase IIb study. As a result, this preliminary analysis, and that of the DSMB, is to recommend no changes to FLAMINGO-01 nor to the investigator brochure, where any new or unexpected safety data might be added.
CEO Snehal Patel commented, "We are pleased that the preliminary safety data from FLAMINGO-01 is consistent with the Phase IIb safety data suggesting that GLSI-100 is well tolerated with no safety signal. The safety data, especially the diameter of injection site reactions, can be measured and thus can be used to assess the magnitude of immune response, along with our GP2 skin test. We look forward to analyzing the immune response data and comparing FLAMINGO-01 preliminary results to the Phase IIb data. There is also the potential that some of the HLA, safety, or immune response data from FLAMINGO-01 will be presented at future scientific conferences as the data continues to mature and patient enrollment continues to accelerate."

Biotech

Health Care

General

GLSI

Greenwich LifeSciences Announced An Update On FLAMINGO-01 Open Label Safety Data

HC Wainwright &amp; Co. analyst Scott Buck reiterates Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) with a Buy and maintains $6 price target.

VERI

HC Wainwright & Co. Reiterates Buy on Veritone, Maintains $6 Price Target

DuPont intends to appoint a Chief Financial Officer for the future Electronics company who will be an external hire with a proven track record of performance at a publicly traded company.
 &nbsp;

Management

DuPont Names Jon Kemp To Be The CEO And Board Member For Future Independent Electronics Public Company

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Bit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) with a Buy and maintains $7 price target.

BTBT

HC Wainwright & Co. Reiterates Buy on Bit Digital, Maintains $7 Price Target

On Monday, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for Monogram Technologies Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>) Monogram <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">mBôs TKA System</a>.
Ben Sexson, Monogram&#8217;s Chief Executive Officer, commented, &#8220;We are particularly excited about the system&#8217;s performance and its potential to advance robotics in orthopedic medicine. We believe we will have strong product-market fit and are well-positioned to make a meaningful impact.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44338422/hasbro-focuses-on-adult-toy-market-amid-declining-toy-sales-report" rel="noreferrer noopener">Hasbro Focuses On Adult Toy Market Amid Declining Sales: Report</a>
Monogram Tech may Market the Monogram mBôs TKA System subject to the Federal Food, Drug, and Cosmetic Act requirements.
The Monogram mBôs TKA System is designed to deliver robotic-assisted total knee arthroplasty.
Monogram believes in the benefits of personalized robotic surgery, enabled by patient-specific imaging (CT-based) and accurate predictive navigation tools. The company sees an opportunity to be part of the ongoing adoption of robotic-assisted procedures.
The company is focused on initial placements with key surgeon KOLs in strategic geographies to establish clinical experience and demonstrate the system&#8217;s advantages in real-world surgical settings.
Upcoming Milestones include:
<ul>
<li>Upgrade cleared system cutting system and other improvements to enhance competitiveness.</li>
<li>Continues to refine and enhance its next-generation technology in parallel with regulatory and clinical trial preparations to improve future competitiveness and expand to new applications.</li>
<li>The company is working to obtain regulatory clearance to initiate clinical trials in India in collaboration with its strategic partner, Shalby Limited, <a href="https://www.benzinga.com/pressreleases/25/02/ac43971740/monogram-technologies-provides-regulatory-update-on-mb-s-tka-system-and-clinical-trial-preparatio" target="_blank" rel="noreferrer noopener">a hospital chain</a>.</li>
<li>The company is working to advance the submission of additional clinical applications to expand the robotic system&#8217;s capabilities and establish it as a versatile, multi-application platform.</li>
</ul>
Cash and cash equivalents totaled $15.7 million as of December 31, 2024. The company continues to direct its resources, focusing on commercializing the mBôs TKA System as <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/ac44292476/correction-monogram-technologies-reports-full-year-2024-financial-results" rel="noreferrer noopener">capital efficiently as possible</a>.
Price Action: MGRM stock closed at $2.33 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/03/44339268/pepsico-reportedly-in-talks-to-acquire-poppi-amid-rising-demand-for-probiotic-drinks" target="_blank" rel="noreferrer noopener">PepsiCo Reportedly In Talks To Acquire Poppi Amid Rising Demand For Probiotic Drinks</a></li>
</ul>

Market-Moving Exclusives

Exclusives

MGRM

EXCLUSIVE: FDA Approves Monogram Technologies' mBôs TKA System For Knee Surgery

EXCLUSIVE: Monogram Technologies Tells Benzinga 'The Company is Preparing for Commercialization and Evaluating Strategies to Support the Adoption of its Robotic-Assisted Technology'

EXCLUSIVE: Monogram Technologies Tells Benzinga Co. Announces FDA 510(k) Clearance For The Monogram mBôs TKA System

HC Wainwright &amp; Co. analyst Scott Buck maintains Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) with a Buy and maintains $6 price target.

HC Wainwright & Co. Maintains Buy on Veritone, Maintains $6 Price Target

Capital One Financial February Credit Card Domestic 30+ Day Performing Delinquencies Rate 4.52%, Net Charge-Offs Rate 6.35% - Filing

Ascendiant Capital analyst Edward Woo maintains Daxor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXR#NASDAQ">DXR</a>) with a Buy and raises the price target from $24.75 to $25.

Ascendiant Capital Maintains Buy on Daxor, Raises Price Target to $25

Ascendiant Capital analyst Edward Woo maintains Aemetis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMTX#NASDAQ">AMTX</a>) with a Buy and raises the price target from $18 to $19.

AMTX

Ascendiant Capital Maintains Buy on Aemetis, Raises Price Target to $19

Billionaire investor Mark Cuban highlights a report that shows that the trade war as a result of President Donald Trump&#8217;s tariffs will significantly impact industries that employ a majority of Trump voters.
What Happened: In a post on the BlueSky social, Mark Cuban asks Trump&#8217;s political opponents, the Democrats, to track local news and reports to talk about the signs of economic pain due to tariffs on Republican-dominated counties. &#8220;The economic pain tariffs can inflict on red states need to be talked about more than anything else right now. It will flip voters.&#8221; posted Cuban.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="593" height="513" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17054358/image-138.png" alt="" class="wp-image-826931" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17054358/image-138.png 593w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17054358/image-138-300x260.png 300w" sizes="(max-width: 593px) 100vw, 593px" /></figure>
Countries such as China, Canada, and Europe have imposed retaliatory tariffs designed to pressure President Trump into reconsidering his strategy. These countermeasures target industries that employ about 7.75 million people across the nation, with 4.48 million of these jobs in counties that supported Trump in the last election, according to a <a href="https://www.nytimes.com/interactive/2025/03/15/business/economy/tariffs-trump-maps-voters.html">New York Times analysis</a>.
Despite Trump&#8217;s assertions that tariffs will boost American jobs, economists warn that the retaliatory tariffs could negate this effect. The targeted industries are likely to experience reduced foreign market sales, leading to lower profits and potential job losses.
Robert Maxim, a fellow at&nbsp;the Brookings Metro, observed that foreign countries have strategically targeted regions and industries where Trump has significant support, including&nbsp;manufacturing hubs in states such as Wisconsin, Indiana, and Michigan, along with southern states like Kentucky and Georgia. It also encompasses regions that manufacture coal, oil, automobile components, and other industrial products.
SEE ALSO: <a href="https://www.benzinga.com/news/25/03/44348205/scaramucci-sees-trouble-ahead-for-musk-trump-relationship-everyone-flames-out-with-trump">Scaramucci Sees Trouble Ahead for Musk-Trump Relationship: &#8216;Everyone Flames Out With Trump&#8217;</a>
Why It Matters: The retaliatory tariffs could also significantly impact industries like farming. During Trump&#8217;s first term, American farmers—a crucial voting bloc for the president—faced trade retaliation from China and other governments, resulting in a decline in U.S. exports of soybeans and other crops. In his Congressional address earlier this month, Trump cautioned farmers about an "an adjustment period" as he&nbsp;imposed the tariffs. 
An analysis&nbsp;by economists at M.I.T., the&nbsp;World Bank, and other institutions also revealed that the&nbsp;retaliatory tariffs imposed on the&nbsp;U.S. during Trump&#8217;s&nbsp;first term had adversely impacted U.S. jobs. This surpassed any advantages gained from Trump&#8217;s tariffs on foreign goods or the subsidies he offered to those impacted by his trade policies.
Earlier former U.S. Treasury Secretary Lawrence H. Summers <a href="https://www.benzinga.com/markets/25/03/44321506/trumps-tariff-policies-a-self-inflicted-wound-says-obama-era-treasury-secretary-larry-summers-economists-weigh-in-as-sp-enters-correction-zone">criticized Trump&#8217;s tariff </a>policies, warning of potential recession risks and negative long-term consequences. Summers described these policies as a &#8220;self-inflicted wound&#8221; that not only increases costs for businesses and consumers but also poses a threat to national security.
Meanwhile, Mark Cuban has several times criticized the Trump administration&#8217;s sole focus on the manufacturing sector and their optimism surrounding tariffs. Instead, Cuban says that the government should shift attention to the profitable service sector and invest heavily on AI. 
READ MORE:
<ul>
<li><a href="https://www.benzinga.com/25/03/44259889/medicare-to-reimburse-guardant-healths-shield-colorectal-cancer-test-at-1495-starting-april-2025-analyst-sees-as-positive-development">Medicare To Reimburse Guardant Health&#8217;s Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Mark Cuban Slams Trump Administration For Inflicting Economic Struggles On A Majority Of Republican Supporters: 'This Could Flip Voters'

Subsequent toH&amp;P's first fiscal quarter of 2025 earnings release on February 5, 2025, the Company received notices of contract suspensions for an additional two rigs from the legacy KCA Deutag rig fleet operating in Saudi Arabia. This brings the Company's total rig suspensions in country to 14 rigs.
President and CEO John Lindsay commented, "As we have mentioned previously, we remain positive on the long-term strategic prospects of having a large-scale drilling presence in the region and are actively pursuing the cost synergies we discussed on the first fiscal quarter earnings conference call."

Guidance

Helmerich & Payne Says Incremental Rig Suspensions Are Disappointing, But Do Not Expect Them To Have Incremental Adverse Material Impact On Financial Position

The feature will be made available via a firmware update to REV7 customers. The Company expects 3D Zone Monitoring to expand its addressable market, simplify customer development, and make its product usability easier than ever before.

OUST

Ouster Unveils On-Sensor 3D Zone Monitoring Feature That Enables Lidar Sensor To Detect Surrounding Objects

EsoBiotec SA, a biotechnology company specializing in in vivo cell therapies, has announced a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44350232/esobiotec-to-be-acquired-by-astrazeneca-to-advance-cell-therapy-ambition" rel="noreferrer noopener">definitive agreement to be acquired</a> by AstraZeneca PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NYSE">AZN</a>).
The agreement represents a major step forward for EsoBiotec, which has demonstrated encouraging early clinical results with its Engineered NanoBody Lentiviral (ENaBL) platform.
AstraZeneca is acquiring all of EsoBiotec&#8217;s outstanding equity for a total of up to $1 billion. The deal includes an initial $425 million payment at closing, with up to an additional $575 million in contingent consideration based on development and regulatory milestones.
The transaction is expected to be finalized in the second quarter of 2025. EsoBiotec will continue operations in Belgium as a wholly owned subsidiary of AstraZeneca.
&#8220;We believe it has the potential to transform cell therapy and will enable us to scale these innovative treatments so that many more patients around the world can access them. EsoBiotec will accelerate and expand the impact of our recent investments and marks a major step forward in realising our ambition to harness the full potential of cell therapy,&#8221; said AstraZeneca Executive Vice President, Oncology Haematology R&amp;D, Susan Galbraith.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44313315/perspective-therapeutics-cancer-focused-radiotherapy-portfolio-has-upside-potentional-says-analyst" rel="noreferrer noopener">Perspective Therapeutics&#8217; Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst</a>
EsoBiotec&#8217;s&nbsp;ENaBL platform utilizes highly targeted lentiviruses to deliver genetic instructions directly to immune cells like T cells. The technology programs these cells to recognize and destroy cancerous cells or autoreactive cells related to immune-mediated diseases.
In contrast to conventional treatments that require extracting cells from patients, modifying them externally, and enduring prolonged manufacturing periods, ENaBL works by enhancing the immune system within the patient&#8217;s body itself, by administering therapies through a simple intravenous (IV) injection.
AstraZeneca held $5.6 billion in <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/901832/000165495425001189/a1107w.htm" rel="noreferrer noopener">cash </a>and equivalents as of December 31.
Price Action: AZN shares traded lower by 0.66% at $77.08 in premarket at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44276870/ionis-pharmaceuticals-partners-with-japan-based-ono-pharmaceutical-for-rare-blood-disease-drug-in-over-800-million-deal" target="_blank" rel="noreferrer noopener">Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal</a></li>
</ul>
Photo via Shutterstock.

Equities

AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details

A renowned industry analyst has said that Nvidia Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://in.benzinga.com/top-stories/25/03/44313558/nvidia-stock-reached-all-time-highs-after-jensen-huangs-ces-keynote-will-next-weeks-gtc-spark-another-surge">GTC 2025 conference</a> could serve as a key turning point for its stock—but only if the company tackles investor concerns around its next-gen AI chips, server production, and the future of scaling laws.
What Happened: In a detailed research note released Sunday, noted analyst Ming-Chi Kuo outlined what investors should watch for at Nvidia's GTC 2025, calling it a potential "short-term catalyst" for the chipmaker's share price rebound—if expectations are met.
"Nvidia's AI server investment trends hinge on three critical issues: the continuing effectiveness of scaling laws, the production ramp-up of new AI servers, and geopolitical uncertainties," Kuo wrote.
The centerpiece of Nvidia's hardware announcements will likely be the B300 AI chip, expected to deliver a 50% performance boost over its predecessor, the B200.
See Also:&nbsp;<a href="https://www.benzinga.com/news/management/25/01/43274796/jensen-huang-loses-20b-in-wealth-how-deepseek-hit-nvidia-stock-and-worlds-richest-people" target="_blank" rel="noreferrer noopener">Jensen Huang Loses $20B In Wealth: How DeepSeek Hit Nvidia Stock And World's Richest People</a>
Kuo says the B300's expanded high-bandwidth memory—from 192GB to 288GB—will be a highlight. It will come in both dual-die (CoWoS-L) and single-die (CoWoS-S) variants, with trial production beginning in the second quarter of 2025 and mass production in the third quarter.
The analyst also noted that the GB300 NVL72 server—designed to replace the widely anticipated but delayed GB200 NVL72—will maintain the same rack dimensions and power needs, making it easier for data centers to upgrade without major overhauls.
"The market widely recognizes the production hurdles of GB200 NVL72," Kuo said. "If Nvidia could highlight real-world data center deployments of GB200 NVL72, underscore the upgrade advantages from B200 to B300, and clarify the B300 production timeline, it could sharpen market expectations for the B300 investment thesis."
He added that edge AI devices are another emerging growth vector, though they will likely take a backseat at GTC, with AI PC solutions such as N1X and N1 expected to debut later this year at Computex.
Despite the conference's strong focus on server infrastructure, Kuo said geopolitical tensions are unlikely to be addressed in any meaningful way.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Nvidia GTC 2025: Hardware Predictions and Investment Trend Analysis Click to read<a href="https://t.co/C05rJD5O8C">https://t.co/C05rJD5O8C</a> <a href="https://t.co/7SdS1WiUlx">pic.twitter.com/7SdS1WiUlx</a>
&mdash; 郭明錤 (Ming-Chi Kuo) (@mingchikuo) <a href="https://twitter.com/mingchikuo/status/1901266994214879331?ref_src=twsrc%5Etfw">March 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.Play
Why It's Important: The upcoming GTC 2025 conference is crucial for Nvidia as it follows a period of fluctuating stock performance. The company&#8217;s stock reached all-time highs after CEO Jensen Huang&#8217;s keynote at CES but has since seen a decline.
The GTC conference, often dubbed the Global AI Conference, is anticipated to be a pivotal moment for Nvidia, potentially sparking another surge in stock value.
In <a href="https://www.benzinga.com/news/24/03/37803088/nvidia-gtc-2024-ceo-huang-highlights-the-past-present-and-future-of-ai-a-new-industry-has-emerged">GTC 2024</a>, Huang underscored the transformative impact of AI, marking the emergence of a new industry.&nbsp;
Price Action: Nvidia&#8217;s stock rose 0.73% in pre-market trading on Monday to $122.56, following a 5.27% surge earlier on Friday, closing at $121.67. Year-to-date, the stock is down 12.03%, according to <a href="http://pro.benzinga.com/">Benzinga Pro</a>.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42260222/how-nvidia-ceos-clever-but-nerdy-pick-up-line-turned-a-homework-proposal-into-marriage-while-building-338-trillion-ai-chip-giant-along-the-way" target="_blank" rel="noreferrer noopener">How Nvidia CEO Jensen Huang's Clever Pick-Up Line Turned A Homework Proposal Into Marriage While Building $3.38 Trillion AI Chip Giant Along The Way</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Tech

NVDA

GTC 2025 Could Reignite Nvidia's Stock Rally, But Only If B300, AI Server Roadmap, And Scaling Concerns Are Addressed, Says Top Analyst

<a href="https://www.reuters.com/technology/intels-new-ceo-lip-bu-tan-has-history-successful-underdog-2025-03-13/" title="https://www.reuters.com/technology/intels-new-ceo-lip-bu-tan-has-history-successful-underdog-2025-03-13/">https://www.reuters.com/technology/intels-new-ceo-lip-bu-tan-has-history-successful-underdog-2025-03-13/</a>

INTC

Reuters Reported New Intel CEO Lip-Bu Tan Plans To Overhaul Chip Design And Manufacturing Businesses; Plans To Restart AI Effort, Produce Chips At Annual Cadence; Plans To Examine Further Cuts To Reduce Bloa

Press Releases

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Legal

Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Comments

Clearmind Medicine

空売り

Clearmind Medicine (NASDAQ:CMND) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル